Drug repositioning in Alzheimer's disease

Frontiers in Bioscience - Scholar

Volumn 7S, Issue 1, 2015, Pages 184-188

  Corbett, Anne ^a   Williams, Gareth ^a   Ballard, Clive ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's; Database; Repositioning; Review; Signature; Transcriptional; Treatment

Indexed keywords

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); DATA BASE; DEMENTIA; DRUG REPOSITIONING; HIGH THROUGHPUT SCREENING; HUMAN; REVIEW; TRANSCRIPTION INITIATION; TRANSCRIPTOMICS; PROCEDURES;

ALZHEIMER DISEASE; DRUG REPOSITIONING; HUMANS;

EID: 84931269774     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s432     Document Type: Review

References (23)

1. Alzheimer's Disease International World Alzheimer Report: http:// www.alz.co.ukresearch/files/WorldAlzheimerReport.pdf. In, (2009)
2. C. Ballard, A. Corbett and S. Sharp: Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease. Expert Rev Neurother, 11(3), 327-9 (2011) DOI: 10.1586/ern.11.13
3. E. Karran, M. Mercken and B. De Strooper: The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov, 10(9), 698-712 (2011) DOI: 10.1038/nrd3505
4. C. Ballard, S. Gauthier, A. Corbett, C. Brayne, D. Aarsland and E. Jones: Alzheimer's disease. Lancet, 377(9770), 1019-31 (2011) DOI: 10.1016/S0140-6736(10)61349-9
5. G. K. Wilcock, S. E. Black, S. B. Hendrix, K. H. Zavitz, E. A. Swabb and M. A. Laughlin: Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol, 7(6), 483-93 (2008) DOI: 10.1016/S1474-4422(08)70090-5
6. R. C. Green, L. S. Schneider, D. A. Amato, A. P. Beelen, G. Wilcock, E. A. Swabb and K. H. Zavitz: Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA, 302(23), 2557-64 (2009) DOI: 10.1.001/jama.2009.1.866
7. S. Zhang, L. Hedskog, C. A. Petersen, B. Winblad and M. Ankarcrona: Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis, 21(2), 389-402 (2010)
8. G. D'Onofrio, F. Panza, V. Frisardi, V. Solfrizzi, B. P. Imbimbo, G. Paroni, L. Cascavilla, D. Seripa and A. Pilotto: Advances in the identification of gamma-secretase inhibitors for the treatment of Alzheimer's disease. Expert Opin Drug Discov, 7(1), 19-37 (2012) DOI: 10.1517/17460441.2012.645534
9. B. Dubois, S. Gauthier and J. Cummings: The utility of the new research diagnostic criteria for Alzheimer's disease. Int Psychogeriatr, 25(2), 175-7 (2013) DOI: 10.1017/S1041610212002098
10. F. Mangialasche, M. C. Polidori, R. Monastero, S. Ercolani, C. Camarda, R. Cecchetti and P. Mecocci: Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev, 8(4), 285-305 (2009) DOI: 10.1016/j.arr.2009.04.002
11. Hoffmann-LaRoche A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease. In, http://clinicaltrials.gov/ct2/show/NCT01224106 (2010)
12. M. Sirota, J. T. Dudley, J. Kim, A. P. Chiang, A. A. Morgan, A. Sweet-Cordero, J. Sage and A. J. Butte: Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med, 3(96), 96ra77 (2011)
13. A. Corbett, G. Williams and C. Ballard: Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease. Pharmaceuticals (Basel), 6(10), 1304-21 (2013) DOI: 10.3390/ph6101304
14. T. T. Ashburn and K. B. Thor: Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov, 3(8), 673-83 (2004) DOI: 10.1038/nrd1468
15. G. Hubsher, M. Haider and M. S. Okun: Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology, 78(14), 1096-9 (2012) DOI: 10.1212/WNL.0b013e31824e8f0d
16. A. Corbett, J. Pickett, A. Burns, J. Corcoran, S. B. Dunnett, P. Edison, J. J. Hagan, C. Holmes, E. Jones, C. Katona, I. Kearns, P. Kehoe, A. Mudher, A. Passmore, N. Shepherd, F. Walsh and C. Ballard: Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov, 11(11), 833-46 (2012) DOI: 10.1038/nrd3869
17. M. J. Marton, J. L. DeRisi, H. A. Bennett, V. R. Iyer, M. R. Meyer, C. J. Roberts, R. Stoughton, J. Burchard, D. Slade, H. Dai, D. E. Bassett, Jr., L. H. Hartwell, P. O. Brown and S. H. Friend: Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med, 4(11), 1293-301 (1998) DOI: 10.1038/3282
18. J. Lamb, E. D. Crawford, D. Peck, J. W. Modell, I. C. Blat, M. J. Wrobel, J. Lerner, J. P. Brunet, A. Subramanian, K. N. Ross, M. Reich, H. Hieronymus, G. Wei, S. A. Armstrong, S. J. Haggarty, P. A. Clemons, R. Wei, S. A. Carr, E. S. Lander and T. R. Golub: The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science, 313(5795), 1929-35 (2006) DOI: 10.1126/science.1132939
19. G. Wei, D. Twomey, J. Lamb, K. Schlis, J. Agarwal, R. W. Stam, J. T. Opferman, S. E. Sallan, M. L. den Boer, R. Pieters, T. R. Golub and S. A. Armstrong: Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell, 10(4), 331-42 (2006) DOI: 10.1016/j.ccr.2006.09.006
20. G. Williams: A searchable cross-platform gene expression database reveals connections between drug treatments and disease. BMC Genomics, 13, 12 (2012)
21. G. Williams: SPIEDw: a searchable platform-independent expression database web tool. BMC Genomics, 14, 765 (2013)
22. M. E. Risner, A. M. Saunders, J. F. Altman, G. C. Ormandy, S. Craft, I. M. Foley, M. E. Zvartau-Hind, D. A. Hosford and A. D. Roses: Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J, 6(4), 246-54 (2006)
23. C. W. Ritchie, A. I. Bush, A. Mackinnon, S. Macfarlane, M. Mastwyk, L. MacGregor, L. Kiers, R. Cherny, Q. X. Li, A. Tammer, D. Carrington, C. Mavros, I. Volitakis, M. Xilinas, D. Ames, S. Davis, K. Beyreuther, R. E. Tanzi and C. L. Masters: Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol, 60(12), 1685-91 (2003) DOI: 10.1001/archneur.60.12.1685